Clear Labs is at the forefront of genomic innovation, delivering fully automated next-generation sequencing (NGS) platforms that transform how laboratories detect and analyze pathogens. Founded in 2014 and headquartered in San Carlos, California, the company has raised over $120 million in funding to democratize genomic testing across clinical diagnostics, food safety, and infectious disease research. Their turnkey Clear Dx platform accelerates detection of infectious disease outbreaks, while their food safety solutions have revolutionized how companies test and analyze food before it reaches consumers.
The company's impact became especially critical during the COVID-19 pandemic, when Clear Labs rapidly expanded its technology from food safety testing to SARS-CoV-2 surveillance and wastewater monitoring. Their automated platform achieved over 50% public health laboratory penetration across the United States, supporting laboratories in states including California, New York, Nebraska, Nevada, and Kansas. With recent collaborations with Labcorp and the launch of oncology-focused NGS workflows, Clear Labs continues to push the boundaries of genomic automation, making sophisticated sequencing technology accessible to laboratories worldwide.